Pfizer News - June 26, 2026

🟢 PFE is trading 2.5% up today after FDA expands IBRANCE breast cancer indication

PFE is trading 2.5% up at $24.27 after the FDA approved an expanded indication for its breast cancer drug, IBRANCE. • The June 24, 2026, decision allows...

Pfizer Wins FDA Approval for IBRANCE, Cutting Breast Cancer Progression Risk 24%

Pfizer received U.S. Food and Drug Administration (FDA) approval for the expanded use of IBRANCE (palbociclib). The approval covers maintenance treatment for...